Error message

The page you requested does not exist. For your convenience, a search was performed using the query events thu 17 may 0930 kidney cancer most lethal urological malignancy these talks are aimed first.

Search results

  1. Dr Catherine Lindon

    ... role of substrate proteolysis in the precisely coordinated events giving rise to two daughter cells at the end of mitosis. The Aurora ...

  2. Dr Athena Matakidou

    ... modify the mouse renal apithelium and replicate the genetic events observed in human renal cell carcinoma. The development of reproducible ...

  3. Dr Mariann Bienz

    ... cell compartment. Our aim is to understand the molecular events underlying Wnt signal transduction. We focus on positively-acting ...

  4. Dr Dario Bressan

    ... for the spatial and temporal control of biological events in vivo. Specifically, I am using photochemically caged ligands and ...

  5. Dr Frank McCaughan

    My research is focused on understanding the early driver events that are critical to the development of squamous lung cancer (SQC) and ...

  6. Professor Gillian Murphy

    ... by trafficking which allows specific localisation in events such as cell invasion. The identification of the importance of specific ...

  7. Dr James Nathan

    Cellular mechanisms of oxygen and metabolite sensing: ...

  8. Dr James Rudd

    ... arteries as a predictor of plaque rupture and clinical events. Additionally, I use non-invasive imaging methods such as PET, MRI and ...

  9. Ms Paola Marco

    ... The inhibitor can be washed out, allowing us to study events in a more flexible way. I will introduce these mutants in RPE cells to ...

  10. Dr Marisa Segal

    ... morphogenesis in S. cerevisiae we have focused on the events that determine SPB asymmetry or spindle polarity, i.e. the mechanisms ...

  11. Dr David Gilligan

    David Gilligan is a Consultant Clinical Oncologist at Addenbrooke's and Papworth Hospitals in Cambridge. He is the Clinical Lead for Acute Oncology at Addenbrooke's. He trained in pre clinical medicine at the University of Edinburgh and clinical...

  12. Mr David Thurtle

    Radiological assessment of prostatic osseous metastases. Robotic-assisted laparoscopic prostatectomy. Early detection of prostate cancer. Risk Prediction in prostate cancer

  13. Professor David Glover

    Our laboratory studies the regulation of progression through mitosis and meiosis in animal cells. The high degree of evolutionary conservation of these regulatory mechanisms means that findings in model organisms are readily applicable to human cells....

  14. Dr Roisin Owens

    Our group works on integrating biological models with electronic devices to generate systems that can be predictive of real biological systems, for drug discovery and therapeutics. We combine expertise in a wide range of disciplines including...

  15. Mr Thierry Lefebvre

    Radiotherapy is often prescribed in oncology clinics to treat solid tumours and to limit the development and the propagation of cancer cells. The lack of oxygenation seen in some tumour regions under chaotic and unrestricted cellular growth constitute a...

  16. Professor Walid Khaled

    My laboratory works on defining the early cellular and molecular events that drive tumour initiation and development. In particular, we focus on how the cell of origin affects the differentiation trajectory of nascent tumour cells and dictates changes...

  17. Mr Adam Palmer

  18. Mrs Angela Godoy

  19. Dr Adrian Kelly

    Biology of MHC class I and class II antigen processing and presentation pathways.

  20. Professor Tony Green

    Tony Green is Professor of Haemato-oncology in the University of Cambridge and honorary Consultant Haematologist at Addenbrookes Hospital. He was appointed Head of the University Department of Haematology (2000-2020), and in 2016 was appointed Director...

  21. Dr Alex Samoshkin

    I have been a Translational Technology Manager in the University of Cambridge since 2017. My primary role is to connect researchers in technology/physical sciences with clinicians and academics to develop new collaborative translational projects. I...

  22. Dr Chiwen Chang

    1. Interaction between NK cells and HLA Class I antigen during immune response. 2. Immunotherapy for cancers and autoimmune diseases.

  23. Dr Christopher Shepherd

  24. Professor Charlotte Coles

    Charlotte Coles is Professor of Breast Cancer Clinical Oncology and NIHR Research Professor at the CRUK Cambridge Centre. Her research aims are to provide breast cancer patients with the best chance of cure with least side effects by personalising...

  25. Professor David Rubinsztein

  26. Dr Elizabeth Soilleux

  27. Dr Alex Cagan

    ... are constantly acquiring mutations. Some of these mutations may influence cellular phenotypes, such as growth, resulting in clonal ... of clones. These processes drive cancer progression and may contribute to ageing.  Due to technical limitations until recently these ...

  28. Mrs Cherry May Sanchez

  29. Dr Daniel Hodson

    ... new therapeutic agents that are entering trials for lymphoma may exert some of their effect though changes in translation and conversely how resistance to these agents may arise by feedback mechanisms acting at the level of mRNA translation. ...

  30. Professor Steve Charnock-Jones

    ... basic biological mechanisms underlying angiogenesis which may be perturbed under pathological conditions and are also open to therapeutic ...

  31. Professor Evis Sala

    Now based in Rome, my research in Cambridge focused on integrated diagnostics, through the clinical development and validation of functional imaging biomarkers to rapidly evaluate treatment response using physiologic and metabolic tumour habitat imaging...

  32. Professor Fiona Gilbert

    ... in this area examining new oncological radiotracers which may be valuable as biomarkers for patient care or in drug development. ...

  33. Dr Gerry Crossan

    ... of these genes, and the characterization of their products may profoundly contribute to our understanding of pathways that maintain ...

  34. Professor Jason Carroll

    ... properties of Pioneer factors since we believe that these may constitute a mechanism of blocking ER from binding to chromatin; an event that may permit inhibition of ER driven transcription, even in situations where ...

  35. Miss Joanne Mayhew

  36. Dr Kevin Chalut

    ... mechanics, and am studying how these physical properties may play a role in biological processes such as tumorogenesis and ...

  37. Dr Iosif Mendichovszky

    ... radiotracers. My research is focused on hybrid imaging of kidney and prostate cancers using single photon emission computed tomography ...

  38. Professor Tim Eisen

    ... clinical interests are the research and management of kidney cancer. In kidney cancer I have been particularly involved in the development of tyrosine ...

  39. Professor Grant Stewart

    ... Research into Renal Cell Cancer (SCOTRRCC), a Scotland-wide kidney cancer biorepository of 1200 patients with high quality clinical data ...

  40. Dr Hannah Harrison

    ... involved in projects investigating risk-stratification for kidney cancer screening and follow-up. Her most rencet project, funded by CRUK, ...

  41. Mr Isaac Toleman

    ... benefit patients. My PhD aims to establish better models for kidney cancer immunotherapy using patient-tissues to predict patient-responses. ...

  42. Dr Marco Sciacovelli

    ... transformation and tumour evolution. We are interested in kidney cancer and we study Fumarate hydratase (FH)- deficient tumours as a ...

  43. Miss Rachel Matthews

    ... heterostructures for the improved detection and treatment of kidney cancer Renal Cell Carcinoma (RCC) affects 13,000 people per ... Aspirate (FNA) could be used to improve the diagnosis of kidney cancer. FNA uses a needle to extract a small number of cells from ...

  44. Dr Richard Sandford

    ... Mutations in PKD1 cause autosomal dominant polycystic kidney disease (ADPKD). PKD1 encodes polycystin-1, a large cell-surface protein ...

  45. Dr Ali Amin Al Olama

    ... has focused on discovery of genetic risk factors of prostate cancer through genome-wide association studies and fine-mapping. I am a core member of an international consortium PRACTICAL (Prostate Cancer Association Group to Investigate Cancer Associated Alterations in the ...

  46. Dr Andreas Bender

    ... large amounts of chemical or biological data related to cancer drug discovery you are very welcome to contact me to see in which way I ...

  47. Dr Alejandra Bruna

    ... aimed to study the effects of the TGF-beta pathway in breast cancer stem cell (BCSC) regulation. To define a role of the TGF-beta pathway in ... of human BCSCs, we have analyzed a panel of breast cancer cell lines that represent the molecular heterogeneity present in primary ...

  48. Professor Antonis Antoniou

    ... component; - the identification and characterisation of cancer risks for genetically susceptible individuals, such as those carrying ...

  49. Dr Alison Dunning

    Work in the Centre for Cancer Genetic Epidemiology "wet lab" involves running very high throughput ... (NGS) studies. We search for genetic risk factors for both cancer susceptibility and treatment-response. In this we collaborate closely ... consortia for breast, ovarian, endometrial and prostate cancer association studies: BCAC http://bcac.ccge.medschl.cam.ac.uk, CIMBA ...

  50. Dr Ashray Gunjur

    ... broadly interested in immuno-oncology and the link between cancer and the gut microbiome, and am undertaking a PhD supervised by Dr David ... between gut microbiota and outcomes in patients with rare cancer types. ...

  51. Dr Ahsan MEMON

    ... this holographic system was deployed to the study of cancer and stem cell shape regulation and the role of effective membrane ...

  52. Dr Aisling Redmond

    ... She completed postdoctoral fellowships in the breast cancer field at the Royal College of Surgeons in Ireland and Cancer Research UK Cambridge Institute (with Professor Jason Carroll), ...

  53. Professor Alan Warren

    ... how defects in this process cause bone marrow failure and cancer predisposition. Assembly of the two subunits of the ribosome, containing ... it is also important for oncogenesis: a novel class of human cancer predisposition disorder has recently emerged that is caused by mutations ...

  54. Dr Arnaud Comment

    ... hyperpolarized biomolecules. Because metabolic fluxes are most often disrupted in pathological tissues, it is of great interest to be ...

  55. Professor Christine Watson

    ... of progenitor cells. The mouse mammary gland is one of the most dramatic examples of physiologically regulated cell death. Our recent ...

  56. Professor Daniel St Johnston

    Most tumours arise from epithelial tissues composed of polarised cells that stick together to form sheets, and a loss of polarity is a hallmark of tumours. We investigate how polarity is established in different epithelial tissues in flies and mammals,...

  57. Dr Joanna Baxter

    The Cambridge Blood and Stem Cell Biobank is a facility of over 6000 viable and nucleic acid samples, the majority from patients with haematological malignancy and clonal blood cell disorders; and the remainder, around 20%, from normal individuals,...

  58. Professor Folma Buss

    ... myosin genes that can be grouped into 12 different classes. Most cell types express multiple myosins - at least 12 different myosins ...

  59. Professor Heike Laman

    ... study other FBPs that we have identified as being among the most frequently rearranged genes in epithelial cancers. The challenge we face ...

  60. Dr Inigo Martincorena

    ... of the genetics of cancer. This has revealed that most cancers carry thousands of mutations in their genomes, accumulated through ...

  61. Dr Helen Robinson

    Discovery and development of novel oncology drugs by inhibiting deubiquitylating enzymes within the DNA damage response, expoliting the concept of synthetic lethality to target tumour but not normal tissues.

  62. Dr John Lizhe Zhuang

    ... (OAC) and its precursor, Barrett's oesophagus (BO). OAC is a lethal cancer often diagnosed at an advanced stage, and its incidence is ...

  63. Dr Trevor Littlewood

    The use of classical, germ-line genetics to define gene function in vertebrates is severely limited by embryonic lethality, developmental compensation and adaptive functional degeneracy, all of which obscure the roles played by genes in adult tissues...

  64. Professor Anna Philpott

    I am interested in the balance between proliferation and differentiation during development and cancer, using a range of models including embryos of the frog Xenopus laevis, mammalian cells including ES cells, and mice. I am particularly interested in...

  65. Dr Anne Warren

    ... tissue sampling and assessment for research projects of the urological malignancies research programme. ...

  66. Dr Richard Benson

    ... radiotherapy and chemoradiotherapy in head and neck and urological cancers, develpoing technical radiotherapy and evaluating treatment ...

  67. Dr Danish Mazhar

    ... in January 2007. His clinical and research interests are in Urological Cancers. He is the Principal Investigator of numerous clinical ...

  68. Professor David Rowitch

    New insight into human neurological diseases has emerged from investigation of normal pathways of brain development. Dr. Rowitch's laboratory investigates Sonic hedgehog (Shh) and BRAF signaling in regulation of neural stem cells that can give rise to...

  69. Professor George Malliaras

    Prof. Malliaras’ group is interested in bioelectronics. Research themes include the design and validation of implantable and cutaneous devices to interface with the brain, with the aim of understanding and treating neurological disorders.

  70. Dr Madeline Lancaster

    The human brain is highly unique in both its size and complexity. Human brain size is greatly expanded compared with even our closest living relatives, chimpanzees and gorillas. On top of this, the greatly expanded number of neurons in the human...

  71. Mr Ray Hsu

    ... the eighth most common malignancy and the third most common urological cancer in the UK. I'm interested in the management of renal cancer, ...

  72. Dr Robert Thomas

    An oncologist specialising in breast, colon and urological cancers, including the treatment of patients with chemotherapy, ...

  73. Dr Annalisa Mupo

    Acute myeloid leukemia (AML) is a molecularly diverse malignancy representing 15-20% of all childhood and around 35% of all adult ...

  74. Miss Nicola Fearnhead

    ... in 2005. Subspecialty interests include advanced pelvic malignancy and exenteration surgery, transanal endoscopic microsurgery, ...

  75. Dr Sarah Jefferies

    ... Gala 5 Study (CRUK grant awarded 2010) and local PI for CNS malignancy, thyroid and head and neck studies ...

  76. Dr Simon Pacey

    ... are: Early phase clinical trials (phase I/II) and Urological malignancy (prostate cancers). My projects are centered around the transition ...

  77. Professor Stefan Marciniak

    ... The process of protein folding can become defective in malignancy. When the level of misfolded proteins within the endoplasmic ...

  78. Dr Adrian Ionescu

    ... up a strong track record with international recognition in these research areas, with 50 publications and two books to date. With some of these publications I have helped shape the new interdisciplinary field of ...

  79. Professor Andrew Flewitt

    ... thin film piezoelectrics. There are two applications of these. Surface acoustic wave (SAW) devices can be used to make microfluidic ...

  80. Dr Alasdair Russell

    ... model systems in a pre-clinical setting. Further, we use these novel models in a range of pre-clinical trials to advance our ...

  81. Mr Angelos Kolias

    ... and evaluation of PET-guided surgery for pituitary adenomas. These are collaborative projects with Mr Richard Mannion (Clinical Lead for ...

  82. Professor Anthony Davenport

    ... imaging using positron emission tomography, to determine how these are altered with disease. Major interests are the role of endothelin-1 in ...

  83. Professor Ben Simons

    ... epidermal maintenance in mouse. Currently, we are extending these ideas to explore cell fate in human epidermis addressing both normal and malignant tissue. These investigations are pursued in close collaboration with experimentalists ...

  84. Dr Basma Greef

    ... of hypoxia response pathways in renal cancer and how these can be harnessed to develop new treatments. My other interests include ...

  85. Professor Adrian Liston

    We are focussed on understanding the biology of regulatory T cells within the ...

  86. Miss Amara Cañizares

  87. Dr Fazlur Rahman Talukdar

    ... (IARC-WHO), France, in 2015. During this tenure, my research aimed to identify DNA methylome alterations linked to esophageal cancer within ...

  88. Dr Kerstin Meyer

    ... analysis of predisposition loci: My experiments are aimed at understanding the mechanisms by which breast cancer risk loci ...

  89. Dr Misha Kapushesky

    ... a universal ecosystem for bioinformatics development, aimed to reduce the chaotic clutter of inefficiency and incompatibility in ...

  90. Dr Nicholas Walton

    ... currently aiding in their search for new techniques aimed at the treatment of breast cancer. ...

  91. Professor Rahul Roychoudhuri

    ... providing targets for development of new therapies aimed at reversing dysfunctional immune responses in cancer. ...

  92. Dr Sujath Abbas

    ... I developed a cost-effective DNA sequencing method (mutREAD) aimed for screening of mutational signatures using FFPE DNA, envisioning its ...

  93. Dr Andre Neves

    ... response to cancer therapy. Currently, I'm planning a first-in-human clinical trial of a novel cell death imaging agent, C2Am. This ...

  94. Dr Bristi Basu

    ... Phase I, II and III clinical trials, including first-in-human and first-in-class studies. My tumour site-specific focus is in ...

  95. Dr Elisa Laurenti

    ... As perturbation of HSC regulatory networks drives the first steps of leukaemia, knowledge of HSC specific molecular responses will ...

  96. Dr Kelly Holmes

    ... CRUK Cambridge Centre Imaging Programme Manager. Kelly has a first class degree in Biochemistry with a year in industry. She completed her ...

  97. Professor Duncan Jodrell

    ... therapies and novel therapeutic combinations, including first into man (phase I) and associated studies.  My research goal is to ...

  98. Dr Laura Blackburn

    ... research and held a workshop on the implementation of the first ctDNA testing services in the NHS, which were facilitating treatment ...

  99. Dr Lori Passmore

    ... of translation to control gene expression, and is the first step in mRNA turnover. The major deadenylase activities are found within ...

Pages